Basic Information
Myclausen
Regulatory Information
EMEA/H/C/001218
Authorised
October 7, 2010
16
April 11, 2024
Company Information
Germany
Eiderstedter Weg 3 14129 Berlin
Passauer Pharma GmbH
Drug Classification
Generic Medicine
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Myclausen. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Myclausen.